Phase III clinical trials evaluating rilotumumab in combination with epirubicin, cisplatin, and capecitabine for MET-positive gastric/GEJ adenocarcinoma have shown that rilotumumab cannot effectively treat gastric/GEJ adenocarcinoma with MET-positive expression.67 Rilotumumab has still not earned a place as a targeted therapy ESCC or EAC. The gene discussed is MET; the disease is gastroesophageal junction adenocarcinoma.